

Journal of Hepatology

CTAT methods

Tables for a “Complete, Transparent, Accurate and Timely account” (CTAT) are now mandatory for all revised submissions. The aim is to enhance the reproducibility of methods.

- Only include the parts relevant to your study
- Refer to the CTAT in the main text as ‘Supplementary CTAT Table’
- Do not add subheadings
- Add as many rows as needed to include all information
- Only include one item per row

If the CTAT form is not relevant to your study, please outline the reasons why:

--

1.1 Antibodies

Name	Citation	Supplier	Cat no.	Clone no.
p-IRAK4		Abcam	Ab216513	
Ly6C		Abcam	Ab15627	E R-MP20
MPO		Invitrogen	MA1-80878	2C7
CYP2E1		Millipore	AB1252	
IRAK4		Enzo	ADI-KAP-ST206-E	
IL-1 β		R&D systems	AF-401	
p-IRAK4		Cell Signalling	11927	D6D7
IRAK1		Cell Signalling	4359	
p-I κ B α		Cell Signalling	2859	14D4
C/EBP β		Cell Signalling	3087	
p-JNK		Cell Signalling	9251	
β -Actin		Cell Signalling	3700	8H10D10
GAPDH		Cell Signalling	5174	D16H11
Caspase 3		Cell Signaling	9665	

1.2 Cell lines

Name	Citation	Supplier	Cat no.	Passage no.	Authentication test method
AML12		ATCC	ATCC [®] CRL-2254 [™]	4-10	STR Profile - Mycoplasma test

1.3 Organisms

Name	Citation	Supplier	Strain	Sex	Age	Overall n number
Mus Musculus		Jackson	C57Bl/6	Female	8-10 weeks	24

IRAK4 kinase-inactive	22	In-house	C57Bl/6	Female	8-10 weeks	24
------------------------------	-----------	-----------------	----------------	---------------	-------------------	-----------

1.4 Sequence based reagents

Name	Sequence	Supplier
M-TNF α	F-CGTCAGCCGATTTGCTATCT R- CGGACTCCGCAAAGTCTAAG	Invitrogen
M-IL-1 β	F-GCAACTGTTCCCTGAACTCAACT R-ATCTTTTGGGGTCCGTCAACT	Invitrogen
M-IL-6	F-GAGGATACCACTCCCAACAGACC R-AAGTGCATCATCGTTGTTCATACA	Invitrogen
M-MCP-1	F-CTCAGCCAGATGCAGTTAACGCC R-GGTGCTGAAGACCTTAGGGCAGAT	Invitrogen
M-F4/80	F-CTTTGGCTATGGGCTTCCAGTCC R-GCAAGGAGGACAGAGTTTATCGTG	Invitrogen
M-CRP	F-CAGACTTTTCCGCACCTTGGCTTT R-AGTGGGTGGTGGTGAAGTACGATT	Invitrogen
M-SAA1	F-ACACCAGGATGAAGCTACTCACCA R-CCCTTGAAAGCCTCGTGAACAAA	Invitrogen
M-Haptoglobin	F-TGCCATTCATGACATGGAGG R-CTCAGGATCCCAGCTGCGTA	Invitrogen
M-Transferrin	F-TGTAGCCTTTGTGAAACACCAGA R-TCGGCAGGGTTCTTTCTT	Invitrogen
M-Albumin	F-CATGACACCATGCCTGCTGAT R-CTCTGATCTTCAGGAAGTGAC	Invitrogen
M- β -Actin	F-CTGTCCCTGTATGCCTCTG R-ATGTCACGCACGATTTCC	Invitrogen
M-CD36	F-GATGACGTGGCAAAGAACAG R-TCCTCGGGGTCCTGAGTTAT	Invitrogen
M-CPT1a	F-CTATGCGCTACTCGCTGAAGG R-GGCTTTTCGACCCGAGAAGA	Invitrogen
M-ACC	F-GTCCCCAGGGATGAACCAATA R-GCCATGCTCAACCAAAGTAGC	Invitrogen
M-FAS	F-AGAGATCCCGAGACGCTTCT R-GCCTGGTAGGCATTCTGTAGT	Invitrogen
M-GAPDH	F-CATCACTGCCACCCAGAAGACTG R-ATGCCAGTGAGCTTCCCGTTCAG	Invitrogen
ON-TARGETplus SMARTpool siRNA targeted against C/EBP β	GAAAAGAGGCGUAUGUAUA; GAUCAACGUGGCUGAGCG; CGGUGGACAAGCUGAGCGA; ACACGGGACUGACGCAACA	Horizon Discovery

1.5 Biological samples

Description	Source	Identifier

1.6 Deposited data

Name of repository	Identifier	Link

1.7 Software

Software name	Manufacturer	Version
ImageJ	National Institute of Health	1.51s

1.8 Other (e.g. drugs, proteins, vectors etc.)

IRAK4 inhibitor	Rigel Inc.	
Clodronate containing liposomes	Encapsula NanoSciences	
Recombinant mouse SAA1	R&D System	

1.9 Please provide the details of the corresponding methods author for the manuscript:

Xiaoxia Li: Department of Inflammation and Immunity, Cleveland Clinic, 9500 Euclid Avenue LRI/NE40, Cleveland, OH 44195, USA, lix@ccf.org, Tel: 1-216-445-8706. Fax: 1-216-444-9329;

Laura E. Nagy: Department of Inflammation and Immunity, Cleveland Clinic, 9500 Euclid Avenue LRI/NE40, Cleveland, OH 44195, USA, nagy13@ccf.org, Tel: 1-216-444-4021, Fax: (216) 636-1493

Jinbo Yang: Tianyan Building/Room 237, Institute of Cancer Biology and Drug Screening, School of Life Sciences, Lanzhou University, Lanzhou, Gansu 730000, China, yangjb@lzu.edu.cn, Tel: 86-0532-85906810, Fax: 86-0532-85906810

2.0 Please confirm for randomised controlled trials all versions of the clinical protocol are included in the submission. These will be published online as supplementary information.

--